Auris Medical Holding AG (NASDAQ:EARS) was upgraded by Zacks Investment Research from a “sell” rating to a “buy” rating in a research note issued on Monday. The firm presently has a $1.25 target price on the stock. Zacks Investment Research’s price objective would suggest a potential upside of 2.46% from the stock’s previous close.

According to Zacks, “Auris Medical Holding AG is a biopharmaceutical company. It focuses on developing therapies for the treatment of hearing loss and tinnitus. The Company has two projects in advanced clinical development: AM-101 for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. Auris Medical Holding AG is headquartered in Zug, Switzerland. “

Other equities analysts also recently issued research reports about the stock. JMP Securities reiterated a “hold” rating on shares of Auris Medical Holding AG in a report on Friday, November 11th. Needham & Company LLC raised their target price on shares of Auris Medical Holding AG from $5.00 to $11.00 and gave the company a “buy” rating in a report on Friday, August 19th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $8.06.

Auris Medical Holding AG (NASDAQ:EARS) opened at 1.22 on Monday. The firm’s market capitalization is $41.86 million. The stock has a 50 day moving average of $1.31 and a 200 day moving average of $2.77. Auris Medical Holding AG has a one year low of $0.84 and a one year high of $7.96.

Auris Medical Holding AG (NASDAQ:EARS) last announced its quarterly earnings results on Thursday, November 10th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.05. During the same quarter in the previous year, the company posted ($0.15) earnings per share. Analysts forecast that Auris Medical Holding AG will post ($1.05) earnings per share for the current year.

A hedge fund recently bought a new stake in Auris Medical Holding AG stock. Advisor Group Inc. bought a new stake in shares of Auris Medical Holding AG (NASDAQ:EARS) during the second quarter, according to its most recent 13F filing with the SEC. The fund bought 66,244 shares of the company’s stock, valued at approximately $277,000. Advisor Group Inc. owned approximately 0.19% of Auris Medical Holding AG as of its most recent filing with the SEC. 26.82% of the stock is owned by institutional investors.

About Auris Medical Holding AG

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

5 Day Chart for NASDAQ:EARS

Receive News & Stock Ratings for Auris Medical Holding AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related stocks with our FREE daily email newsletter.